PubMed

Display Settings: Abstract

Clin Cancer Res. 2011 Aug 18. [Epub ahead of print]

High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More?

de Groot JF.

Dept. of Neuro-Oncology, U.T. M.D. Anderson Cancer Center.

Abstract

Targeting angiogenesis in glioblastoma rapidly reduces vascular permeability and contrast enhancement on MRI and prolongs progression-free survival (PFS). The long-term efficacy of bevacizumab and other antiangiogenic agents is limited, however, because of the rapid development of resistance. Alternative dosing approaches may be one mechanism of prolonging therapeutic efficacy.

PMID: 21852387 [PubMed - as supplied by publisher]

LinkOut - more resources